Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (47 ops.)
Latest filing published 20 Oct 2026 for CYTOKINETICS INC, €11k.
Filing timeline
BuySaleEdward M. Kaye MD
Insider track record
Disclosed buys
0
Disclosed sells
47
Signal history
Edward M. Kaye MD: trading record in brief
Edward M. Kaye MD has filed 118 disclosures from January 25, 2016 to October 20, 2026, at four companies: Stoke Therapeutics, Inc. (48, Director), Cytokinetics Inc (46, Director), Sarepta Therapeutics, Inc. (22, President, CEO & CMO) and Avidity Biosciences, Inc. (2, Director).
The 47 sales total EUR 16,297,046, median EUR 231,156, and no purchase is recorded. The largest, EUR 2,150,501, is dated September 22, 2016 at Sarepta; next come EUR 1,613,960 on December 1, 2025 at Cytokinetics and EUR 974,099 on December 17, 2020 at Stoke. The rest of the record is 41 grants, 29 option exercises and one other filing.
The year 2025 weighs 42 filings, ahead of 2016 (16) and 2024 (13); 2017 has 6. The last twelve months hold 31 filings, 17 of them sales.
At Stoke Therapeutics, Inc., 31 of Kaye's trades fall within 30 days of a trade by Barry Ticho, 27 near Jonathan Allan and 12 near Adrian R. Krainer; at Cytokinetics Inc, Fady Ibraham Malik has 10 and Robert I. Blum 8, in the same direction.
Companies and markets linked to Edward M. Kaye MD
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations118 total
195 shares@ US$63.920.0001% mcap0.5% of flowCommon StockSEC:0001061983-26-000105:0
26,250 shares0Common StockSEC:0001522780-26-000007:0
11,930 shares@ US$32.00720.023% mcap13.6% of flowCommon StockSEC:0001522780-26-000007:1
637 shares@ US$32.46810.0013% mcap0.7% of flowCommon StockSEC:0001522780-26-000007:2
151 shares@ US$82.620.0001% mcap0.8% of flowCommon StockSEC:0001061983-26-000081:0
2,933 shares@ US$76.090.0025% mcap14.1% of flowCommon StockSEC:0001061983-26-000066:0
2,851 shares0Common StockSEC:0001061983-26-000058:0
191 shares@ US$65.370.0001% mcap2.6% of flowCommon StockSEC:0001061983-26-000040:0
26,250 shares0Common StockSEC:0001522780-26-000002:1
35,500 shares0Common StockSEC:0001522780-26-000002:0
6,692 sharesCommon StockSEC:0001193125-26-082136:0
197 shares@ US$63.440.8% of flowCommon StockSEC:0001061983-26-000006:0
8,274 shares@ US$32.523.2% of flowCommon StockSEC:0001522780-25-000010:1
1,331 shares@ US$33.100.5% of flowCommon StockSEC:0001522780-25-000010:2
3,825 shares@ US$31.43874.3% of flowCommon StockSEC:0001522780-25-000010:0
5,222 shares@ US$30.761.9% of flowCommon StockSEC:0001522780-25-000009:1
1,231 shares@ US$31.320.5% of flowCommon StockSEC:0001522780-25-000009:2
6,367 shares@ US$31.332.3% of flowCommon StockSEC:0001522780-25-000009:3
1,681 shares@ US$31.150.6% of flowCommon StockSEC:0001522780-25-000009:4
500 shares@ US$31.850.2% of flowCommon StockSEC:0001522780-25-000009:5
26,250 shares0Common StockSEC:0001522780-25-000009:0
661 shares@ US$29.560.2% of flowCommon StockSEC:0001522780-25-000008:1
405 shares@ US$30.140.1% of flowCommon StockSEC:0001522780-25-000008:2
419 shares@ US$30.340.1% of flowCommon StockSEC:0001522780-25-000008:3
651 shares@ US$30.850.2% of flowCommon StockSEC:0001522780-25-000008:4
25 of 118 declarations
